Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBA NASDAQ:IMRX NASDAQ:LRMR NASDAQ:RNTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$1.42+4.4%$1.10$0.82▼$4.08$364.83M0.236.45 million shs6.59 million shsIMRXImmuneering$5.53+8.4%$4.86$2.90▼$10.08$329.96M0.411.49 million shs1.59 million shsLRMRLarimar Therapeutics$3.61+5.9%$3.58$2.71▼$6.42$354.24M0.832.89 million shs2.05 million shsRNTXRein Therapeutics$0.97-4.0%$1.04$0.86▼$2.18$86.39M1.35586,999 shs159,552 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+5.19%+17.36%+51.77%+0.71%-61.73%IMRXImmuneering+8.43%+9.50%+40.71%-2.30%+38.25%LRMRLarimar Therapeutics+5.87%+12.46%+16.45%-29.08%+8.73%RNTXRein Therapeutics-3.96%-0.82%+2.25%-36.60%-37.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$1.42+4.4%$1.10$0.82▼$4.08$364.83M0.236.45 million shs6.59 million shsIMRXImmuneering$5.53+8.4%$4.86$2.90▼$10.08$329.96M0.411.49 million shs1.59 million shsLRMRLarimar Therapeutics$3.61+5.9%$3.58$2.71▼$6.42$354.24M0.832.89 million shs2.05 million shsRNTXRein Therapeutics$0.97-4.0%$1.04$0.86▼$2.18$86.39M1.35586,999 shs159,552 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+5.19%+17.36%+51.77%+0.71%-61.73%IMRXImmuneering+8.43%+9.50%+40.71%-2.30%+38.25%LRMRLarimar Therapeutics+5.87%+12.46%+16.45%-29.08%+8.73%RNTXRein Therapeutics-3.96%-0.82%+2.25%-36.60%-37.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 2.20Hold$4.67228.64% UpsideIMRXImmuneering 2.86Moderate Buy$16.57199.66% UpsideLRMRLarimar Therapeutics 3.09Buy$12.71252.20% UpsideRNTXRein Therapeutics 2.00Hold$7.00621.65% UpsideCurrent Analyst Ratings BreakdownLatest RNTX, LRMR, IMRX, and AKBA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2026IMRXImmuneering Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$17.007/8/2026IMRXImmuneering Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$17.007/2/2026LRMRLarimar Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.007/1/2026AKBAAkebia Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.006/30/2026LRMRLarimar Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/30/2026LRMRLarimar Therapeutics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$7.00 ➝ $5.006/26/2026RNTXRein Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026IMRXImmuneering Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/1/2026IMRXImmuneering OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/1/2026RNTXRein Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $8.005/27/2026LRMRLarimar Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$9.00(Data available from 7/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$236.20M1.61N/AN/A$0.12 per share11.83IMRXImmuneeringN/AN/AN/AN/A$3.38 per shareN/ALRMRLarimar TherapeuticsN/AN/AN/AN/A$0.94 per shareN/ARNTXRein TherapeuticsN/AN/A$0.05 per share17.66($1.07) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$5.34M-$0.08N/AN/AN/A-8.83%-62.72%-5.66%8/6/2026 (Estimated)IMRXImmuneering-$56.03M-$1.17N/AN/AN/AN/A-31.93%-29.92%8/12/2026 (Estimated)LRMRLarimar Therapeutics-$165.67M-$2.06N/AN/AN/AN/A-134.14%-96.00%8/13/2026 (Estimated)RNTXRein Therapeutics-$49.87M-$1.90N/AN/AN/AN/AN/A-68.14%N/ALatest RNTX, LRMR, IMRX, and AKBA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026IMRXImmuneering-$0.30-$0.21+$0.09-$0.21N/AN/A5/15/2026Q1 2026RNTXRein Therapeutics-$0.49-$0.19+$0.30-$0.19N/AN/A5/14/2026Q1 2026LRMRLarimar Therapeutics-$0.53-$0.31+$0.22-$0.31N/AN/A5/7/2026Q1 2026AKBAAkebia Therapeutics-$0.01-$0.03-$0.02-$0.03$51.67 million$53.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/ARNTXRein TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.331.401.33IMRXImmuneeringN/A32.4532.45LRMRLarimar TherapeuticsN/A4.294.29RNTXRein TherapeuticsN/A0.400.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%IMRXImmuneering67.65%LRMRLarimar Therapeutics91.92%RNTXRein Therapeutics90.89%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics4.30%IMRXImmuneering22.90%LRMRLarimar Therapeutics4.50%RNTXRein Therapeutics1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430268.26 million256.72 millionOptionableIMRXImmuneering6064.70 million49.88 millionNot OptionableLRMRLarimar Therapeutics30103.88 million99.21 millionOptionableRNTXRein Therapeutics985.54 million84.26 millionN/ARNTX, LRMR, IMRX, and AKBA HeadlinesRecent News About These CompaniesRein Therapeutics, IncJune 29, 2026 | edition.cnn.comAll You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to BuyJune 17, 2026 | zacks.comRein Therapeutics Expands Phase 2 RENEW Trial into United KingdomJune 11, 2026 | globenewswire.comRein Therapeutics Inc RNTXJune 7, 2026 | morningstar.comMRein Therapeutics (NASDAQ:RNTX) Director Buys $16,747.50 in StockMay 29, 2026 | insidertrades.comRein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment OptionMay 18, 2026 | globenewswire.comInsider Buying: Rein Therapeutics (NASDAQ:RNTX) Insider Purchases 25,000 Shares of StockMay 14, 2026 | insidertrades.comRein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common StockApril 30, 2026 | globenewswire.comRein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary FibrosisApril 29, 2026 | globenewswire.comRein Therapeutics Stock Short Interest Report | NASDAQ:RNTX | BenzingaApril 14, 2026 | benzinga.comRein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary FibrosisMarch 3, 2026 | markets.businessinsider.comRein Therapeutics (RNTX) price target increased by 25.00% to 10.20February 4, 2026 | msn.comAnalysts Offer Insights on Healthcare Companies: Rein Therapeutics (RNTX), Zimmer Biomet Holdings (ZBH) and Theravance Biopharma (TBPH)January 23, 2026 | theglobeandmail.comRein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary FibrosisJanuary 20, 2026 | manilatimes.netMRein Therapeutics (NASDAQ:RNTX) Shares Down 0.8% – Here’s WhyJanuary 9, 2026 | defenseworld.netDVoss Capital, Lp Buys 104,183 Shares of Rein Therapeutics (NASDAQ:RNTX) StockNovember 19, 2025 | insidertrades.comRein Therapeutics (RNTX) Price Target Decreased by 20.00% to 8.16November 17, 2025 | msn.comRein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPFNovember 6, 2025 | finance.yahoo.comRein Therapeutics upgraded to Buy from Hold at BrooklineNovember 4, 2025 | msn.comWhy Is Rein Therapeutics Stock Trading Higher On Monday?November 3, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRNTX, LRMR, IMRX, and AKBA Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$1.42 +0.06 (+4.41%) Closing price 07/8/2026 04:00 PM EasternExtended Trading$1.40 -0.02 (-1.76%) As of 07/8/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Immuneering NASDAQ:IMRX$5.53 +0.43 (+8.43%) Closing price 07/8/2026 04:00 PM EasternExtended Trading$5.45 -0.08 (-1.43%) As of 07/8/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Larimar Therapeutics NASDAQ:LRMR$3.61 +0.20 (+5.87%) Closing price 07/8/2026 04:00 PM EasternExtended Trading$3.76 +0.15 (+4.02%) As of 07/8/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Rein Therapeutics NASDAQ:RNTX$0.97 -0.04 (-3.96%) Closing price 07/8/2026 04:00 PM EasternExtended Trading$0.97 +0.00 (+0.10%) As of 07/8/2026 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Exxon Could Be the Market's Next Big Comeback Stock Why Penguin Solutions May Be the Smartest AI Infrastructure Stock The Market Just Got Shaken—These 3 ETFs May Come Out Stronger Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns A Market Panic Just Discounted the AI Highway's Tollbooth Vertex’s Crinetics Deal Balances Growth with Integration Risk Apple and Broadcom Forge a Decade-Long Silicon Fortress These 3 Cash-Flow Stocks Give Investors More Than Just Growth Potential Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
